Lataa...
PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target
Urothelial cancer (UC) is one of the most common cancers in Europe and is also one of the costliest to treat. When first line therapies show initial success, around 50% of cancers relapse and proceed to metastasis. In this study we assessed the Protein inhibitor of activated signal transducers and a...
Tallennettuna:
| Julkaisussa: | PLoS One |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Public Library of Science
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6804980/ https://ncbi.nlm.nih.gov/pubmed/31639157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0224085 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|